Clinical trials: Anti-PD-1
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC
Systemic Anti-tumor Activity and Safety of the Combination of SBRT and Concurrent PD-1 Blockade in Metastatic RCC.
Prior research has indicated that stereotactic body radiotherapy (SBRT) can effectively trigger systemic anti-tumor immune response.
- Trial name
- NCT06327178
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Extensive Stage Small Cell Lung Cancer
To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
- Trial name
- NCT05468489
- Testing
- Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide)
- Where
- 67 sites in United States
- Volunteers
- 200 people
- Sponsor
- Shanghai Henlius Biotech
Melanoma, Skin, Melanoma Stage Iii
MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns]
The goal of this observational study is to learn about if new biomarkers such as gut microbiota and molecular genetics melanoma features could predict clinical radiological and pathological response to neoadjuvant monotherapy…
- Trial name
- CRISTINA (NCT06299878)
- Testing
- Gut microbiota analysis
- Where
- Russia
- Volunteers
- 72 people
- Sponsor
- Russian Academy of Medical Sciences
SHR-1210, Anlotinib
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
This study was designed to explore the clinical efficacy of SHR-1210 in combined with Anlotinib in the treatment of second- or above- line advanced or metastatic esophageal squamous cell cancer patients, in order to find a better…
- Conditions
- SHR-1210, Anlotinib, Advanced Esophageal Squamous Cell Cancer
- Trial name
- NCT04797507
- Testing
- SHR-1210 plus Anlotinib
- Volunteers
- 33 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Renal Cell Carcinoma
Inflammatory Markers (ICC, MCVL) and Nivolumab Response: Predicting Immunotherapy Success in Metastatic RCC
This study is an observational study aimed at investigating the potential of new inflammatory markers to predict treatment response in patients with metastatic renal cell carcinoma (mRCC) undergoing anti-PD-1 antibody nivolumab…
- Trial name
- IMNR (NCT06607809)
- Where
- Turkey (Türkiye)
- Volunteers
- 99 people
- Sponsor
- Dr. Lutfi Kirdar Kartal Training and Research Hospital
Epithelial Ovarian Cancer, Non-small Cell Lung Cancer
ITIL-306 in Advanced Solid Tumors
ITIL-306-201 is a phase 1a/1b, multicenter, clinical trial evaluating the safety and feasibility of ITIL-306 in adult participants with advanced solid tumors whose disease has progressed after standard therapy.
- Conditions
- Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT05397093
- Testing
- ITIL-306
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Instil Bio
Non-Small Cell Lung Cancer
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
This is a phase 1/2 study of combined treatment with dupilumab (anti-IL-4Ra) and cemiplimab (anti-PD-1) in patients with early-stage, resectable non-small cell lung cancer (NSCLC).
- Trial name
- NCT06088771
- Testing
- Dupilumab, Cemiplimab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Cutaneous Melanoma
NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma
This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice.
- Trial name
- NEOSENT (NCT07680699)
- Testing
- Anti-PD1 Therapy Timing
- Where
- Brazil
- Volunteers
- 250 people
- Sponsor
- AC Camargo Cancer Center
Solid Tumors
The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Participants With Advanced Solid Tumors
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose)…
- Trial name
- NCT02660034
- Testing
- Tislelizumab, Pamiparib
- Where
- 29 sites in United States, Australia and 4 more
- Volunteers
- 229 people
- Sponsor
- BeiGene
Malignant Melanoma
Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract
This is a single-center, open-label, single-arm phase II clinical study to exploratory observe and evaluate the efficacy and safety of anti-PD-1 antibody (Camrelizumab for Injection) in patients with malignant melanoma of the…
- Trial name
- NCT04593485
- Testing
- Camrelizumab for injection
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Non Small Cell Lung Cancer
Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the leading cause of cancer mortality worldwide and in the U.K alone; there are 38,000 new cases of non-small cell lung cancer (NSCLC) a year.
- Trial name
- PARIS (NCT03245177)
- Testing
- Pembrolizumab, Radiotherapy
- Sponsor
- Prof Corinne Faivre-Finn
Colorectal Cancer
Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC
This is an open-label, multicenter, phase Ib/II combined trial of sitagliptin, XELOX chemotherapy regimen, and PD-1 monoclonal antibody in the treatment of proficient mismatch repair locally advanced colorectal cancer.
- Trial name
- Neo-CD (NCT07365592)
- Testing
- Oxaliplatin, Capecitabine, Anti-PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma
Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL
This study evaluates the addition of Sintilimab to current 2nd line salvage therapy of Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) for patients with relapsed or refractory Diffuse Large B-Cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT04659434
- Testing
- Sintilimab
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Qian Wenbin
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Advanced Solid Tumor
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
This is a Phase 1 study to evaluate the safety, tolerability, PK, and preliminary efficacy of IO-108 monotherapy and in combination with anti-PD-1 monoclonal antibody pembrolizumab or tislelizumab in adult patients with advanced…
- Trial name
- NCT05508100
- Testing
- IO-108, IO-108 + pembrolizumab, IO-108 + tislelizumab
- Where
- 14 sites in China
- Volunteers
- 38 people
- Sponsor
- Immune-Onc Therapeutics
Non Small Cell Lung Cancer
Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLC
Subjects will be eligible for this study if they are about to start on a drug called nivolumab for lung cancer. Some patients' cancers respond to nivolumab but a majority of patients do not.
- Trial name
- NO3DEXPL (NCT03371992)
- Testing
- Nivolumab, 3D-EX, Evaluation of Response by RECIST
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Nilogen Oncosystems
Head and Neck Squamous Cell Carcinoma HNSCC
Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCC
This multicenter, randomized, open-label, parallel-controlled clinical trial aims to evaluate the efficacy and safety of surgery combined with postoperative chemoradiotherapy versus finotonlimab plus induction chemotherapy…
- Trial name
- NCT07751276
- Testing
- Neoadjuvant Finotonlimab Plus Chemotherapy, Surgery, Postoperative Finotonlimab Maintenance
- Volunteers
- 142 people
- Sponsor
- Yanjie Zhang, MD
Cancer
Exploratory Study of BO-112 in Adult Patients With Aggressive Solid Tumors
Part 1: 16 to 32 patients with aggressive solid tumors from whom biopsies can be obtained, will receive BO-112 through IT administration.
- Trial name
- NCT02828098
- Testing
- Part 1: BO-112, Part 2: BO-112
- Where
- 7 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Highlight Therapeutics
Advanced Solid Tumor, Solid Tumor
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
This is an open-label, multicenter, and nonrandomized dose escalation and dose expansion study to evaluate BGB-26808 as monotherapy or in combination with tislelizumab in participants with advanced solid tumors.
- Trial name
- NCT05981703
- Testing
- BGB-26808, Tislelizumab, Chemotherapy
- Where
- 28 sites in United States, Australia and 2 more
- Volunteers
- 337 people
- Sponsor
- BeOne Medicines
Multiple Myeloma
Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I/II trial studies the side effects and best dose of lenalidomide and pidilizumab and to see how well they work in treating patients with multiple myeloma that has come back (relapsed) or has not responded to treatment…
- Trial name
- NCT02077959
- Testing
- lenalidomide, pidilizumab, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.